Mease et al. PsA - Early DMARD initiators (=<1 year following diagnosis) greater improvement in outcomes than late initiators (at least in MDA) in CorEvitas. @RheumNow #ACR22 Abstr#1493
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry - ACR Meeting Abstracts
